
- May 2013 Skin & Eye Health
- Volume 79
- Issue 5
Study Suggests Link Between Type 2 Diabetes and Low Melatonin
Women with low levels of melatonin may be at a higher risk for developing type 2 diabetes, according to a recent study published in the April 3, 2013, issue of the Journal of the American Medical Association.
The study included 370 women from the U.S. Nurses’ Health Study who developed type 2 diabetes from 2000 to 2012 and 370 non-diabetic controls. Melatonin levels were measured through urine and blood samples before the development of diabetes. When analyzing the relationship between melatonin and diabetes development, the researchers evaluated other risk factors such as demographics, eating habits, and sleep patterns.
Women with the lowest levels of melatonin were 2.17 times more likely to develop type 2 diabetes than women with the highest melatonin levels.
“While there is a correlation between melatonin and insulin resistance, we cannot tell from this study if low melatonin is the cause,” said Dr. Joel Zonszein, director of the clinical diabetes center at Montefiore Medical Center in New York City, in a press release. “We are far away from melatonin as a treatment.”
The authors conclude that more research is needed to determine if low melatonin levels are a risk factor for type 2 diabetes in the general population.
Articles in this issue
over 12 years ago
Self-Care for Eyes and Skinover 12 years ago
Generic Drugs: Maintaining Our Prerogative to Dispenseover 12 years ago
Put Your Best Face Forward: Treatment of Acne Vulgarisover 12 years ago
Ouch! Relief for Minor Wounds and Burnsover 12 years ago
Transdermal Drug Delivery Systems: The Skinny on Cutaneous Reactionsover 12 years ago
Antiplatelet Effects of Aspirin: Which NSAIDs Interact?over 12 years ago
Seeing Redover 12 years ago
Time to Check That Technologyover 12 years ago
Alcon Laboratories, Inc's IlevroNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.